-
1 week ago | 
jdsupra.com | Dion Bregman |Theodore Rand |Alexander Stein
USPTO Acting Director Coke Morgan Stewart recently issued a decision discretionarily denying five petitions for inter partes review (IPR) filed by iRhythm against patents owned by Welch Allyn based on a factor that had not been used before—the petitioner’s longstanding awareness of an issued patent.
-
1 week ago | 
morganlewis.com | Theodore Rand |Alexander Stein |Dion Bregman
USPTO Acting Director Coke Morgan Stewart recently issued a decision discretionarily denying five petitions for inter partes review (IPR) filed by iRhythm against patents owned by Welch Allyn based on a factor that had not been used before—the petitioner’s longstanding awareness of an issued patent.
-
2 months ago | 
morganlewis.com | Tawni Lisseth Henderson |jacob peterson |Alexander Stein |Dion Bregman
The USPTO has launched a sweeping recalibration of its post-grant proceedings at the PTAB, signaling a decisive pivot back toward discretionary denials of patent challenges.
-
Mar 14, 2025 | 
jdsupra.com | Maria Doukas |jacob peterson |Alexander Stein
As 2025 unfolds, changes across the patent landscape are unfolding. From agency leadership transitions to proposed legislation and evolving AI-related policies, these shifts could impact patent prosecution, post-grant proceedings, and strategic considerations for companies and practitioners. This LawFlash provides a high-level overview of key developments impacting proceedings at the USPTO, including (1) leadership and operational changes, (2) legislative initiatives, and (3) policy revisions.
-
Mar 13, 2025 | 
lexology.com | Maria Doukas |Alexander Stein |jacob peterson
As 2025 unfolds, changes across the patent landscape are unfolding. From agency leadership transitions to proposed legislation and evolving AI-related policies, these shifts could impact patent prosecution, post-grant proceedings, and strategic considerations for companies and practitioners. This LawFlash provides a high-level overview of key developments impacting proceedings at the USPTO, including (1) leadership and operational changes, (2) legislative initiatives, and (3) policy revisions.
-
Mar 12, 2025 | 
morganlewis.com | Maria Doukas |Alexander Stein |jacob peterson
As 2025 unfolds, changes across the patent landscape are unfolding. From agency leadership transitions to proposed legislation and evolving AI-related policies, these shifts could impact patent prosecution, post-grant proceedings, and strategic considerations for companies and practitioners. This LawFlash provides a high-level overview of key developments impacting proceedings at the USPTO, including (1) leadership and operational changes, (2) legislative initiatives, and (3) policy revisions.
-
Jan 27, 2025 | 
jdsupra.com | Conor J Ball |Dion Bregman |Alexander Stein
On January 14, 2025, the Federal Circuit in Lynk Labs Inc. v. Samsung Electronics Co. Ltd.
-
Nov 11, 2024 | 
jdsupra.com | Dion Bregman |Rachna Ram |Alexander Stein
The US Patent and Trademark Office (USPTO) implemented 37 CFR § 42.75 on October 31, 2024, establishing a formal framework for Director Review of Patent Trial and Appeal Board (PTAB) proceedings. During her tenure, Director Kathi Vidal has actively worked to promulgate formal rules to permanently adopt existing interim, pilot, or other informal procedures at the PTAB.
-
Nov 8, 2024 | 
morganlewis.com | Dion Bregman |Alexander Stein |Rachna Ram
The US Patent and Trademark Office (USPTO) implemented 37 CFR § 42.75 on October 31, 2024, establishing a formal framework for Director Review of Patent Trial and Appeal Board (PTAB) proceedings. During her tenure, Director Kathi Vidal has actively worked to promulgate formal rules to permanently adopt existing interim, pilot, or other informal procedures at the PTAB.
-
Oct 13, 2024 | 
biorxiv.org | Alexander Stein |Benjamin Werner
AbstractGenetic intra-tumour heterogeneity (gITH) is a universal property of all cancers. It emerges from the interplay of cell division, mutation accumulation and selection with important implications for the evolution of treatment resistance. Theoretical and data-driven approaches extensively studied gITH in ageing somatic tissues or cancers at detection. Yet, the expected patterns of gITH during and after treatment are less well understood.
